Full Text View
Tabular View
No Study Results Posted
Related Studies
A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C
This study is ongoing, but not recruiting participants.
Study NCT01591460   Information provided by Hoffmann-La Roche

First Received on May 2, 2012.   Last Updated on June 18, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis C, Chronic
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis, Chronic
More general conditions related to this trial
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
boceprevir
peginterferon alfa-2a [Pegasys]
ribavirin (Copegus]
Additional drug interventions recognized in this trial
Interferon-alpha
Peginterferon alfa-2a
Ribavirin
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antiviral Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Hoffmann-La Roche


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services